AI-Driven Oversight: Transforming Clinical Trials

Missed Our SCOPE EU session or want more insights? Explore Here

Experts Serena Smith and Chris Axford recently presented at SCOPE EU, discussing how AI can revolutionize clinical trial oversight. Below, you can review the abstract of their presentation and download an additional resource for a deeper dive into these advancements.

Title:

Clinical Trial Oversight at the Tipping-Point: Building an AI-Native Decision-Intelligence Layer for End-to-End Clinical Trials

Abstract:

Clinical-trial oversight is approaching a breaking point, inundated by torrents of operational, clinical and laboratory data—and further complicated by a constellation of stakeholders, each needing a different view of the truth. While sponsors still rank cross-source data harmonization as a top pain point, global AI adoption has jumped to 72% in the past year, and Gartner projects that by 2027 half of all business decisions will be augmented or automated by AI agents.

This session positions trial oversight squarely at that technological tipping-point. We will explore how converging technology advances, can be fused into an AI-native decision-intelligence layer, addressing existing clinical trial challenges and turning fragmented oversight into a real-time, personalized decision system.

Using the forthcoming Clinical Decision Suite as an illustrative vignette, we will map the key themes to consider in order maximize the opportunities of AI technology to support the end-to-end delivery of clinical trials.

Presenters:

• Serena Smith
  Exec. Director Strategy & Innovation​
• Chris Axford
  Sr. Director, Business Insights, Clinical Research 

Clinical Decision Suite demo